Catalyst Seeks FDA Approval of Firdapse for Treatment of LEMS

Catalyst Pharmaceuticals filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for Firdapse (amifampridine) as a treatment for Lambert-Eaton myasthenic syndrome (LEMS). “We are pleased to reach this regulatory milestone and believe that our NDA submission contains all of the necessary information…